N/A
N=2,004
Study of Colorectal Cancer Screening Options
Colon Cancer
Bottom Line
View on ClinicalTrials.gov: NCT05987709 ↗Enrolled (actual)
2,004
Serious AEs
0.0%
Results posted
Dec 2025
Primary outcome: Primary: Assess Colorectal Cancer Screening Completion — 305; 130 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- GuardantSHIELD Blood Test (Diagnostic_test)
- Age
- Adult, Older Adult · 45+ yrs
- Sex
- All
- Sponsor
- Kaiser Permanente
- Primary completion
- Dec 2022
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Assess Colorectal Cancer Screening Completion |
305; 130 | — |
| SECONDARY Assess the Percentage of Participants Who Completed Follow-up Testing. |
11; 7 | — |
Summary
The investigators propose to evaluate Guardant Health's commercially available colorectal cancer screening assay(Guardant SHIELD) in individuals who are not up to date with CRC screening.
Eligibility Criteria
Inclusion Criteria
- Age 45-75
- Received a FIT test in the last 3-9 months yet did not return their FIT
- Upcoming appointment or willing to reschedule an appointment at KPNW within 2 - 6 weeks
- Able and willing to provide informed consent if in the intervention arm
Exclusion Criteria
- On KPNW's do not contact list
- Having a legal authorized representative
- Non-English speakers
Data sourced from ClinicalTrials.gov (NCT05987709). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.